179 related articles for article (PubMed ID: 31861382)
21. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells.
Momeny M; Eyvani H; Barghi F; Ghaffari SH; Javadikooshesh S; Hassanvand Jamadi R; Esmaeili F; Alishahi Z; Zaghal A; Bashash D; Samani FS; Ghaffari P; Dehpour AR; Tavangar SM; Alimoghaddam K; Ghavamzadeh A
Anticancer Drugs; 2018 Nov; 29(10):1011-1020. PubMed ID: 30096128
[TBL] [Abstract][Full Text] [Related]
23. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract][Full Text] [Related]
24. RGS5 decreases the proliferation of human ovarian carcinoma‑derived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia.
Wang D; Xu Y; Feng L; Yin P; Song SS; Wu F; Yan P; Liang Z
Oncol Rep; 2019 Jan; 41(1):165-177. PubMed ID: 30365142
[TBL] [Abstract][Full Text] [Related]
25. HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis.
Li X; Zhang NX; Ye HY; Song PP; Chang W; Chen L; Wang Z; Zhang L; Wang NN
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(10):4126-4135. PubMed ID: 31173282
[TBL] [Abstract][Full Text] [Related]
26. NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer.
Zhu J; Wu G; Song L; Cao L; Tan Z; Tang M; Li Z; Shi D; Zhang S; Li J
EBioMedicine; 2019 May; 43():238-252. PubMed ID: 31047858
[TBL] [Abstract][Full Text] [Related]
27. Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer.
Paik ES; Kim TH; Cho YJ; Ryu J; Choi JJ; Lee YY; Kim TJ; Choi CH; Kim WY; Sa JK; Lee JK; Kim BG; Bae DS; Han HD; Ahn HJ; Lee JW
Sci Rep; 2020 Mar; 10(1):4904. PubMed ID: 32184452
[TBL] [Abstract][Full Text] [Related]
28. MiR-539-3p promotes the progression of epithelial ovarian cancer by targeting SPARCL1.
Gong YB; Fan XH
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2366-2373. PubMed ID: 30964161
[TBL] [Abstract][Full Text] [Related]
29. Songorine suppresses cell growth and metastasis in epithelial ovarian cancer via the Bcl‑2/Bax and GSK3β/β‑catenin signaling pathways.
Zhang H; Dong R; Zhang P; Wang Y
Oncol Rep; 2019 May; 41(5):3069-3079. PubMed ID: 30896826
[TBL] [Abstract][Full Text] [Related]
30. Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling.
Wu G; Cao L; Zhu J; Tan Z; Tang M; Li Z; Hu Y; Yu R; Zhang S; Song L; Li J
Clin Cancer Res; 2019 Feb; 25(3):1022-1035. PubMed ID: 30279231
[TBL] [Abstract][Full Text] [Related]
31. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
32. Physical interaction of STAT1 isoforms with TGF-β receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer.
Tian X; Guan W; Zhang L; Sun W; Zhou D; Lin Q; Ren W; Nadeem L; Xu G
J Exp Clin Cancer Res; 2018 May; 37(1):103. PubMed ID: 29751820
[TBL] [Abstract][Full Text] [Related]
33. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
Zhang L; Zhang S; Li A; Zhang A; Zhang S; Chen L
Int J Mol Med; 2018 Dec; 42(6):3065-3072. PubMed ID: 30221689
[TBL] [Abstract][Full Text] [Related]
34. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
35. Tripartite Motif-Containing Protein 59 (TRIM59) Promotes Epithelial Ovarian Cancer Progression via the Focal Adhesion Kinase(FAK)/AKT/Matrix Metalloproteinase (MMP) Pathway.
Zhang P; Zhang H; Wang Y; Zhang P; Qi Y
Med Sci Monit; 2019 May; 25():3366-3373. PubMed ID: 31062766
[TBL] [Abstract][Full Text] [Related]
36. BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.
Han W; Zhang Y; Niu C; Guo J; Li J; Wei X; Jia M; Zhi X; Yao L; Meng D
Cancer Lett; 2019 Mar; 445():45-56. PubMed ID: 30654010
[TBL] [Abstract][Full Text] [Related]
37. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
38. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
[TBL] [Abstract][Full Text] [Related]
39. Long noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.
Qiu JJ; Lin XJ; Tang XY; Zheng TT; Zhang XY; Hua KQ
Int J Cancer; 2020 May; 146(9):2588-2598. PubMed ID: 31577838
[TBL] [Abstract][Full Text] [Related]
40. Response of Cisplatin Resistant Skov-3 Cells to [Pt(
De Castro F; Benedetti M; Antonaci G; Del Coco L; De Pascali SA; Muscella A; Marsigliante S; Fanizzi FP
Molecules; 2018 Sep; 23(9):. PubMed ID: 30205612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
